Press releases
Number of shares and votes in Oncopeptides Regulatory
March 29, 2018
Stockholm - March 29, 2018 - Oncopeptides AB (Nasdaq Stockholm, ONCO) today announces that the number of shares and votes in Oncopeptides has changed as a result of the issue of 3,980,000 shares, which was carried out in March 2018
Read more
Oncopeptides strengthens its management team with Dr Christian Jacques as EVP Clinical Strategy and Chief Scientific Officer
March 26, 2018
Stockholm – March 26th, 2018 - Oncopeptides AB (Nasdaq Stockholm: ONCO) today announced that it has broaden its management team with the appointment of Dr Christian Jacques as Executive Vice President Clinical Strategy and Chief Scientific Officer (CSO). Dr Jacques has more than 25 years of experience in clinical development of new chemical entity’s within hematology-oncology leading to approval of several innovative pharmaceuticals in oncology and hematology, including pomalidomide
Read more
Oncopeptides has completed a directed share issue of approximately SEK 314 million Regulatory
March 22, 2018
NOT FOR PUBLICATION, DISTRIBUTION OR RELEASE, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES OF AMERICA, CANADA, JAPAN, SOUTH AFRICA OR AUSTRALIA OR ANY OTHER JURISDICTION IN WHICH THE DISTRIBUTION OR RELEASE WOULD BE UNLAWFUL
Read more
Oncopeptides intends to make a directed share issue Regulatory
March 21, 2018
NOT FOR PUBLICATION, DISTRIBUTION OR RELEASE, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES OF AMERICA, CANADA, JAPAN, SOUTH AFRICA OR AUSTRALIA OR ANY OTHER JURISDICTION IN WHICH THE DISTRIBUTION OR RELEASE WOULD BE UNLAWFUL
Read more
Additional patent protection for Ygalo® granted in Japan until October 2033
March 8, 2018
Stockholm - March 8, 2018 - Oncopeptides AB (Nasdaq Stockholm; ONCO) announced today that the Japanese Patent Office (JPO) recently issued a notice that they will grant an additional Japanese patent to Oncoeptides AB
Read more
Oncopeptides AB Year-end report 2017 Regulatory
February 22, 2018
Stockholm, Sweden – Oncopeptides AB (Nasdaq Stockholm; ONCO) today announced the Year-end report 2017
Read more
Oncopeptides presented survival data from the phase II-study O-12-M1 of Ygalo® (melflufen) at the 59th Annual Meeting of ASH today Regulatory
December 10, 2017
Stockholm – December 10th, 2017 - Oncopeptides AB (Nasdaq Stockholm: ONCO) announced today that the first survival data were presented at the annual meeting of the American Society of Hematology from the phase II-study O-12-M1 in late-stage patients with Relapsed Refractory Multiple Myeloma (RRMM)
Read more
Oncopeptides presented interim data from the ongoing phase II study HORIZON with Ygalo® (melflufen) at the 59th Annual Meeting of ASH today Regulatory
December 9, 2017
Stockholm – December 9th, 2017 - Oncopeptides AB (Nasdaq Stockholm: ONCO) announced today that interim data was presented at the American Society of Hematology from the ongoing phase II study HORIZON, treating late-stage patients with Relapsed Refractory Multiple Myeloma (RRMM) that are also refractory to pomalidomide and/or daratumumab
Read more
Oncopeptides AB Interim Report July – September 2017 Regulatory
November 15, 2017
Stockholm, Sweden – Oncopeptides AB (Nasdaq Stockholm; ONCO) today announced the third quarter 2017 report. “The data from our study, O-12-M1, provides us with an increased degree of comfort regarding a positive clinical outcome in our pivotal study OCEAN”
Read more
Oncopeptides to attend the Jefferies Healthcare Conference in London on November 16th
November 7, 2017
Stockholm – November 7, 2017 - Oncopeptides AB (Nasdaq Stockholm: ONCO) announced today that they will attend Jefferies annual Healthcare Conference in London on November 16th
Read more